tbuckley/cabot-search huggingface dataset:
Primary pulmonary adenocarcinoma in a 13-year-old girl with absence of EGFR gene mutation
Authors: Y. Lim, T. T. Ghim, B. Park, H. Park, J. Lee, J. Hah, E. Jung
Journal: Journal of Clinical Oncology (2006)

17150 Non-small cell carcinoma of lung frequently associated with cigarette smoking is extremely rare in children. We, here, describe a 13-year-old female diagnosed with stage IV pulmonary adenocarcinoma. She had never started smoking. Yet, she had environmental tobacco smoking exposure in the household as her father had been a long-time heavy smoker. The patient presented with 6-month history of chronic recurring cough. A CT of chest showed a mass obstructing the left upper lung bronchus with a collapse of the lung in the left upper segment. A bronchoscopic biopsy revealed a poorly differentiated adenocarcinoma. There were bilateral pleural and pericardial effusions along with multiple nodular lesions in the brain, liver and bones suggesting of wide dissemination of the lung cancer. In her past, there was no history of radiation exposure or immune deficiency. She had never had any other childhood cancer treated previously. Interestingly, there was no evidence of EGFR gene mutation in the genomic DNA analysis of the tumor specimen. In the hospital, she was treated with palliative chemotherapy initially starting with gefitinib and later with regimen of navelbine, gemcitabine and cisplatin combination with no response. A palliative radiation therapy to mediastinum was added mainly to relieve her airway obstruction. Currently, after 6 months from initial diagnosis, she remains clinically stable and ambulatory without tumor progression on docetaxel monthly chemotherapy cycle. Our report here suggests that a primary pulmonary adnenocarcinoma without previous radiation exposure to chest in a child who never had smoking may occur. It might be that environmental tobacco smoking exposure may have had a deleterious impact. No significant financial relationships to disclose.
Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval.
Authors: Pavel Nemec, Henrieta Greslikova, Petr Kuglik, Hana Filkova, Romana Zaoralova, Vladimira Vranova, Jana Smejkalova, Petra Vidlakova, Alexandra Oltova, Roman Hajek
Journal: Blood (2007)
HGF Measurement in AL Amyloidosis.
Authors: Julie Abraham, Estelle Desport, Benoit Marin, Sebastien Bender, Corinne Lacombe, Stéphane Girault, Stéphane Moreau, Fatima Yagoubi, Dominique Bordessoule, Franck Bridoux, Arnaud Jaccard
Journal: Blood (2009)
Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.
Authors: Mohamad Mohty, Le Quoc-Hung, Franck E Nicolini, Frederic Garban, Gerard Socie, Michel Attal, Noel- Jean Milpied, Bruno Lioure, Pierre Bordigoni, Ibrahim Yakoub-Agha, Jean-Henri Bourhis, Bernard Rio, Eric Deconinck, Marc Renaud, Jean-Luc Harousseau, Didier Blaise, Mauricette Michallet
Journal: Blood (2008)
GW26-e2339 miR-199a-3p, a Biomarker of Simulated Microgravity Induced Cardiac Remodeling
Authors: Guohui Zhong, Shukuan Ling, Hongxing Li, Yuheng Li, Weijia Sun, Zi Xu, Hailin Song, Dengchao Cao, Xinxin Yuan, Dingsheng Zhao, Qi Li, Xiaoyan Jin, Jinping Song, Yingxian Li
Journal: Journal of the American College of Cardiology (2015)
Pooled RCTs: In patients with acute ischemic stroke, alteplase increases intracerebral hemorrhage
Authors: Lucas McCarthy
Journal: Annals of Internal Medicine (2016)

Source Citation Whiteley WN, Emberson J, Lees KR, et al; Stroke Thrombolysis Trialists' Collaboration. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15:925-33. 27289487
Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study
Authors: Christine L Kempton, Michael Recht, Anne Neff, Michael Wang, Tyler W. Buckner, Amit Soni, Doris Quon, Michelle Witkop, Lisa Boggio, David L Cooper
Journal: Blood (2015)
ZIO-101, a Novel Organic Arsenic, Inhibits Human Myeloma Cell Growth in a SCID-hu Model.
Authors: Richard A. Campbell, Eric Sanchez, Haiming Chen, Lauren Turker, Mingjie Li, Olivia Trac, Dror Shalitin, Melinda S. Gordon, Shen Pang, Benjamin Bonavida, Jonathan Said, Barbara Wallner, Robert P. Gale, James R. Berenson
Journal: Blood (2006)
Phase III multicenter randomized study of concurrent twice-a-day radiotherapy with and without cisplatin-5FU (BiRCF) in unresectable pharyngeal carcinoma. Results at 18 months (FNCLCC-GORTEC)
Authors: R. J. Bensadoun, O. Dassonville, A. Ramaioli, N. Magné, K. Benezery, P. Y. Marcy, G. Poissonnet, C. Lemanski, S. Bourdin, J. Tortochaux
Journal: Journal of Clinical Oncology (2004)

5504 Background: Between November 1997 and March 2002, 171 following patients were enrolled in this phase III multicenter trial. Methods: Regardless lymph nodes status, not previously treated, strictly unresectable carcinomas of oro- and hypopharynx were included. Eligibility criteria: KPS≥70, age≤75, acceptable renal, cardiac, and biological parameters. Patients (pts) were followed during the overall treatment (trt) time (7 weeks), with enteral nutritional support and mucositis prevention. RT: Primary tumor and satellite nodes : 2 opposed lateral fields, 60Co or 5–6 MV photons, 2 fractions (fr.) of 1.2 Gy/d., 5 d a week, with no split (D1->D46). Total tumor doses : 80.4 Gy/46 d. (oropharynx), 75.6 Gy/44 d. (hypopharynx). CT (arm B): Cisplatin 100 mg/m2(D1); 5FU, continuous infusion (D1->D5), 750 mg/m2/d cycle 1; 430 mg/m2 cycles 2 and 3. Cisplatin and 5FU pharmacokinetics were performed. Pharmacokinetically guided 5FU dose adaptation was used at D4. 2nd cycle at D22; 3rd at D43. Results: At 18 months, 163 evaluable pts (123 oropharynx, 40 hypopharynx). For the whole population, disease free survival (DFS) and specific survival (SS) were significantly better in arm B. DFS: 54.32% vs 37.5% (p=0.002); SS: 48.15% vs 35.8% (p=0.05). For the 123 oropharynx (108 males, mean age 53 yr, median follow-up 18 mo, max 72 mo). T4: 79; panpharyngeal T3: 44; T2N3: 5; N2b/N2c: 60; N3: 17; N0: 16. CT (arm B): mean dose of Cisplatin 1st cycle 92 mg/m2; 2nd cycle 87 mg/m2; mean dose of 5FU 1st cycle 730 mg/m2/d (5 d); 2nd and 3rd cycle 426 mg/m2/d (5 d). Grade 3–4 acute mucositis 51 % arm A / 82 % arm B; Grade 2–3 dermatitis 34 % / 65 %; Grade 3–4 neutropenia 39 % (arm B). SS: 47.88% arm A vs 69% arm B (p<0.04). DFS: 39.6% arm A vs 66.1% arm B (p<0.002); median global survival: 10 mo arm A vs 17 mo arm B (p<0.05). For the 40 hypopharynx, however, the difference between the 2 arms was not significant. Conclusions: Those results confirm that for oropharyngeal carcinoma, radio-chemotherapy do better than radiation alone, even with the best fractionation and dose-intensity schedule. No significant financial relationships to disclose.
GW26-e5394 3D heart model printing of complex congenital heart disease based on the low dose cardiac CT images: initial experience in China
Authors: Kun Liu, Bin Lu, Zhe Zheng, Enshi Wang, Yue Shi, Yang Gao, Weihua Yin, Shoujun Li, Yu Chang, Shengshou Hu
Journal: Journal of the American College of Cardiology (2015)
GW26-e2933 The Application and Prognostic Evaluation of STEMI Clinical Pathway in the Treatment of EPCI Patients
Authors: Yijun Zhou, Zi Ye, Xiong Yan, Kaipang Guang, Jiang Peng, Xu Jia, Xiaoxiong Xiao, Hong Zhan
Journal: Journal of the American College of Cardiology (2015)
Predictive value of circulating VEGF in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin and docetaxel (Italian phase II DOCETUX Study)
Authors: F. Di Fabio, C. Pinto, E. Bucca, S. Giaquinta, A. S. Fabricio, V. Mutri, S. Michilin, F. L. Rojas Llimpe, C. Funaioli, M. Gion, A. A. Martoni
Journal: Journal of Clinical Oncology (2008)

15605 Background: The aim of this study was to evaluate the predictive significance of circulating VEGF modifications in advanced gastric or GEJ cancer pts treated with cetuximab plus cisplatin and docetaxel as first-line therapy. Methods: Pts received cetuximab 400 mg/m2 iv followed by 250 mg/m2 iv weekly, cisplatin 75 mg/m2 iv and docetaxel 75 mg/m2 iv d1 every 3 weeks, for a maximum of 6 cycles; cetuximab alone was continued in CR/PR/SD. Anti-tumor activity was assessed by CT-scan every 6 weeks. Venous blood was collected on day 1 before therapy and on days 4, 8, 22, 43 during treatment. We have measured VEGF both in serum, and in CTAD plasma in order to evaluate both VEGF produced and release in vivo (CTAD plasma) and VEGF also produced and/or transported and released by platelets. VEGF levels were assessed using a quantitative sandwich enzyme immunoassay (Quantikine Human VEGF Immunoassay, R&D Systems, Minneapolis, MN, USA). The method's lower detection limit was 10 pg/ml, the intra- and interassay variation coefficients were below 8% within a VEGF concentration ranging from 10 to 2000 pg/ml. Results: 21 pts were evaluated. Pt characteristics were: 19 M, 2 F; primary site: stomach 20, GEJ 1; disease stage: locally advanced 1, metastatic 20. 19 pts were evaluable for response. The objective responses (RECIST) were: 1 CR, 10 PR, 5 SD (16 pts with disease control) and 3 PD. The median VEGF basal value was 158.4 pg/ml in plasma and 369.1 pg/ml in serum. The median VEGF level showed a 42.7% decrease in plasma and 7.6% in serum 4 days after the start of therapy, and decreases of 31.6% and 17.5%, respectively, after 8 days. 14 patients altogether showed a reduction in median VEGF levels by at least 40% within 8 days from the start of treatment. The reduction by at least 40% in basal VEGF levels observed after just 4 days in plasma (median 95.2 pg/ml) and serum (median 307.5 pg/ml) determinations was statistically correlated with disease control (plasma: p = 0.045; serum: p = 0.040). Conclusions: These preliminary data suggest that cetuximab plus cisplatin and docetaxel may induce a modulation in VEGF circulating levels, while an early VEGF reduction could be predictive of treatment activity. No significant financial relationships to disclose.
Letter to the editor: A norovirus intervariant GII.4 recombinant in Victoria, Australia, June 2016: the next epidemic variant? Reflections and a note of caution
Authors: Jannik Fonager, Lasse Dam Rasmussen, Thea Kølsen Fischer
Journal: Eurosurveillance (2016)

Preview this article: Letter to the editor: A norovirus intervariant GII.4 recombinant in Victoria, Australia, June 2016: the next epidemic variant? Reflections and a note of caution, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/41/eurosurv-21-30372-3-1.gif
GW26-e0741 Fractional Flow Reserve Guided Percutaneous Coronary Intervention improves clinical outcome with reduced cost in Chinese real world practice
Authors: Po Hu, Mengyao Tang, Wenchao Song, Jun Jiang, Yong Su, Xianbao Liu, Changling L, Xinyang Hu, Jianan Wang
Journal: Journal of the American College of Cardiology (2015)
Validation of the Low Risk Prognostic Scoring System (LR-PSS) in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center
Authors: Helena Pomares, Isabel Sánchez-Ortega, Esther Alonso, Javier Grau, Rafael F. Duarte, Anna Sureda, Montserrat Arnan
Journal: Blood (2015)
Treatment of Children &amp; Adolescents with Early Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma with a Low Intensity Short Duration Chemotherapy Regimen [CVP] - on Behalf of the EuroNet-PHL Group.
Authors: Ananth G. Shankar, Stephen Daw, Georgina Hall, Stephanie Gorde-Grosjean, Christine Mauz Koerholz, Dieter Korholz, William H. Wallace, Dirk Hasenclever, Judith Landman-Parker
Journal: Blood (2006)
NHS must find ways to speed access to new drugs and technologies
Authors: Nigel Hawkes
Journal: BMJ (2016)

New drugs, diagnostic tools, and healthcare technologies could be adopted more quickly if the NHS took a fresh approach, according to the final report of the Accelerated Access Review.1

Streamlining the drug approval process could cut four years off the time needed to bring new medicines to the clinic, the review said. This would be made up by saving 12-18 months in the drug approval process; by cutting delays in approval by the National Institute for Health and Care Excellence (NICE), which typically takes up to two years; and in NHS commissioning and adoption, which usually takes another two years.

“We need to act now to make the most of a tidal wave of new drugs and technologies that are being developed,” …
The Frequency of Occurrence of Minimal Residual Disease into Different Prognostic Groups of Patients with Chronic Lymphocytic Leukemia
Authors: Aleksei Kuvshinov, Sergei Voloshin, Irina Martynkevich, Ludmila Martynenko, Andrei Garifullin, Elizaveta Kleina, Kudrat Abdulkadyrov
Journal: Blood (2015)
High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML
Authors: Caroline A Heckman, Mika Kontro, Tea Pemovska, Samuli Eldfors, Henrik Edgren, Evgeny Kulesskiy, Muntasir Mamun Majumder, Riikka Karjalainen, Bhagwan Yadav, Agnieszka Szwajda, Naga Poojitha Kota Venkata, Astrid Murumägi, Disha Malani, Alun Parsons, Petteri Hintsanen, Henrikki Almusa, Jesús María López Martí, Pekka Ellonen, Pirkko Mattila, Maija Lepistö, Sonja Lagström, Minna Suvela, Satu Mustjoki, Janna Saarela, Tero Aittokallio, Olli Kallioniemi, Krister Wennerberg, Kimmo Porkka
Journal: Blood (2012)
Advance care planning: Stability and provider perceptions
Authors: M. Schutzer, D. S. Dizon, M. Politi, C. Linkletter, J. S. Gass, C. Bandera, S. Miller, M. A. Clark
Journal: Journal of Clinical Oncology (2008)

20734 Background: Previously we reported that 43% of women with female-defined cancer named more than one person to the advance care planning roles of emergency contact (EC) and health care proxy (HCP), and to primary support (PS). However, the stability of these roles and providers’ understanding of them remains a critical question. We conducted a follow-up study to (1) determine how stable patients’ EC, PS, and HCP were over time and (2) assess concordance between whom healthcare providers recognize and whom patients name to these roles. Methods: Following Institutional Review Board approval, patients who originally participated in the first survey were re-contacted and a telephone survey used to re-identify their EC, PS, and HCP. Patients also named providers who played important roles in their care. We then approached providers named by each individual patient and asked them to list who they recognized as the patient’s EC, PS, and HCP. Results: Of 215 original participants, 113 (53%) took part in this study, of whom 81% were in remission. Thirty-one (14%) declined to participate, 44 (20%) were deceased, and 27 (13%) were not reachable. Median time between surveys was 23 months. At re-survey, 84 patients (74%) named one person for all 3 roles. This includes 65/83 (78%) women with partners and 19/30 (63%) single women. The choice for EC, PS, and HCP was stable over time for 73%, 76%, and 88% of women respectively (Table). However, if more than one person was named, significant instability was observed for each role. Comparing provider responses (n=194) to those from patients, concordance was 68% for EC, 59% for PS, and only 51% for HCP. Conclusion: In this follow-up study, 26% named more than one person to the roles of EC, PS, and HCP, likely related to the changing composition of our sample where the majority of respondents were in remission. We found that naming more than one person was associated with increased instability in responses over the interval between studies. This may explain the poor concordance between patient and provider responses for EC, PS, and HCP. Stability (S) over time in women naming one vs. more than one person for EC, PS, and HCP EC S (%) PS S (%) HCP S (%) Total (n=113) 82 (73) 86 (76) 99 (88) One person named (n=84) 86 (81) 76 (91) 79 (94) More than one person named (n=29) 14 (48) 10 (35) 20 (69) p-value 0.001 < 0.001 0.001 No significant financial relationships to disclose.
Lymphoproliferative Response to Herpes Simplex Virus, Cytomegalovirus, Epstein-Barr Virus, Varicella Zoster Virus, Human Herpes Virus 6, 7 and 8 Antigen Stimulation in Pediatric Allogeneic Stem Cell Transplant Recipients.
Authors: Frankie Wai Tsoi Cheng, Paul Kay Sheung Chan, Wing Kwan Leung, Vincent Lee, Matthew MK Shing, Chi Kong Li, Ting Fan Leung
Journal: Blood (2009)
Effect of Intravenous Busulfan Versus Total Body Irradiation on Donor Chimerism and Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (AlloSCT) in Mice.
Authors: Jie Wang, Xiaotao Zhou, Heather Symons, Moshe Y. Levy, Ephraim J. Fuchs
Journal: Blood (2005)
Influence of Homemade and Commercial Fibrin Sealant on Alveolar Bone Healing - an Experimental Study.
Authors: Maria Elvira P. Correa, Oslei P. Almeida, Danyel Peres, Marcelo C. Alves, Fernando F. Costa, Joyce M. Annechinno-Bizzachi, Maria Lourdes Barjas-Castro
Journal: Blood (2004)
The Changes on hematopoietic Stem Cells and mIcroenvIronment of childhood acute Lymphoblastic Leukemia at dIagnosIs and after chemotherapy
Authors: Mee Jeong Lee, Chan-Jeoung Park, Chan-Hee Yoon, Seongsoo Jang, Hyun-Sook Chi, Ho Joon Im, Bo Eun Kim, Jong Jin Seo
Journal: Blood (2011)
Genetic and Clinical Characterization of 45 Acute Leukemia Patients with MLL Gene Rearrangements From a Single Institution.
Authors: Nuno Cerveira, Susana Lisboa, Cecília Correia, Susana Bizarro, Joana Santos, Lurdes Torres, Joana Vieira, João D Barros-Silva, Dulcineia Pereia, Cláudia Moreira, Claus Meyer, Tereza Oliva, Ilída Moreira, Ângelo Martins, Luisa Viterbo, Vitor Costa, Rolf Marschalek, Armando Pinto, Jose Mario Mariz, Manuel R. Teixeira
Journal: Blood (2012)
Abstract C15: Neutrophil elastase (NE) induces epithelial-mesenchymal transition (EMT) via upregulation of inhibitor of DNA binding 1 (ID1)
Authors: Julia Kargl, Alyssa Gregory, Hye Youn Yang, Stephanie Busch, Heather Metz, A. McGarry Houghton
Journal: Cancer Research (2016)

Abstract Neutrophil elastase is a neutrophil-derived serine protease with broad substrate specificity. We have previously shown that NE promotes lung tumor growth in vitro and in vivo and that NE is capable of entering tumor cell endosomes in a clathrin-dependent fashion. Epithelial-mesenchymal transition (EMT) is a fundamental event for primary tumors to metastasize to distant sites. Altered gene and protein expression causes changes in cell morphology and behavior resulting in the loss of attachment to neighboring cells, intravasation, and migration into distant tissue. However, the entities residing within the tumor microenvironment that drive EMT are poorly understood. We identified NE, expressed and released by tumor-associated neutrophils, as such an entity. We found that NE induces EMT-like morphology and behavior in several cancer cell lines as well as upregulates genes (Snail and Twist) and proteins (N-cadherin, α-SMA, Fibronectin and Vimentin) associated with EMT. Furthermore, NE provokes tumor cell migration and invasion in vitro and is required for metastasis formation in vivo. Besides known EMT markers we identified significant upregulation of inhibitor of DNA binding 1 (ID1) in tumor cells in the presence of NE. Increased ID1 expression was previously shown to correlate with tumor progression and metastasis. Clathrin-dependent NE internalization is required for both ID1 expression and the EMT-like phenotype. We localized NE in different compartments of tumor cells and found it predominantly in the nuclear fraction; more specifically, NE is located in the chromatin-bound fraction, indicating a potential role in chromatin remodeling and transcriptional regulation. Additionally, the proteolytic activity of NE was measured in the nuclear and chromatin-bound fractions and is required for induction of ID1 expression and EMT-like behavior. Taken together, these data suggest the importance of NE-induced ID1 expression in metastasis formation. Citation Format: Julia Kargl, Alyssa Gregory, Hye Youn Yang, Stephanie Busch, Heather Metz, A. McGarry Houghton. Neutrophil elastase (NE) induces epithelial-mesenchymal transition (EMT) via upregulation of inhibitor of DNA binding 1 (ID1). [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr C15.
The Presence of M Protein Is Strongly Associated with Very Poor Prognosis in Patients with Extranodal Diffuse Large B-Cell Lymphoma
Authors: Hideaki Nitta, Yasuhito Terui, Masahiro Yokoyama, Yuko Mishima, Noriko Nishimura, Kyoko Ueda, Tadahiro Gunji, Yoshiharu Kusano, Norihito Inoue, Anna Takahashi, Naoko Tsuyama, Kengo Takeuchi, Kiyohiko Hatake
Journal: Blood (2015)
Low-molecular-weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting
Authors: N.J.M. London, K. Varty, M. Thompson, R.D. Sayers, P.R.F. Bell, VijayV. Kakkar, RobertA. Edmondson, AlexanderT. Cohen
Journal: The Lancet (1994)
Improvement of Long-Term Survival after High-Dose Melphalan in Patients with Light Chain Amyloidosis Responding to Induction Chemotherapy.
Authors: Anja Mangatter, Stefan O Schoenland, Marion Hansberg, Tilmann Bochtler, Sascha Dietrich, Peter Dreger, Kai Neben, Anthony Ho, Hartmut Goldschmidt, Ute Hegenbart
Journal: Blood (2008)
A Four-Gene Promoter Methylation Marker Panel Consisting of <i>GREM1, NEURL, LAD1,</i> and <i>NEFH</i> Predicts Survival of Clear Cell Renal Cell Cancer Patients
Authors: Iris J.H. van Vlodrop, Sophie C. Joosten, Tim De Meyer, Kim M. Smits, Leander Van Neste, Veerle Melotte, Marcella M.L.L. Baldewijns, Leo J. Schouten, Piet A. van den Brandt, Jana Jeschke, Joo Mi Yi, Kornel E. Schuebel, Nita Ahuja, James G. Herman, Maureen J. Aarts, Fred T. Bosman, Wim Van Criekinge, Manon van Engeland
Journal: Clinical Cancer Research (2016)

Purpose: The currently used prognostic models for patients with nonmetastatic clear cell renal cell carcinoma (ccRCC) are based on clinicopathologic features and might be improved by adding molecular markers. Epigenetic alterations occur frequently in ccRCC and are promising biomarkers. The aim of this study is to identify prognostic promoter methylation markers for ccRCC.Experimental Design: We integrated data generated by massive parallel sequencing of methyl-binding domain enriched DNA and microarray-based RNA expression profiling of 5-aza-2'-deoxycytidine-treated ccRCC cell lines to comprehensively characterize the ccRCC methylome. A selection of the identified methylation markers was evaluated in two independent series of primary ccRCC (n = 150 and n = 185) by methylation-specific PCR. Kaplan-Meier curves and log-rank tests were used to estimate cause-specific survival. HRs and corresponding 95% confidence intervals (CI) were assessed using Cox proportional hazard models. To assess the predictive capacity and fit of models combining several methylation markers, HarrellC statistic and the Akaike Information Criterion were used.Results: We identified four methylation markers, that is, GREM1, NEURL, LAD1, and NEFH, that individually predicted prognosis of patients with ccRCC. The four markers combined were associated with poorer survival in two independent patient series (HR, 3.64; 95% CI, 1.02-13.00 and HR, 7.54; 95% CI, 2.68-21.19). These findings were confirmed in a third series of ccRCC cases from The Cancer Genome Atlas (HR, 3.60; 95% CI, 2.02-6.40).Conclusions: A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts outcome of patients with ccRCC and might be used to improve current prognostic models. Clin Cancer Res; 23(8); 2006-18. ©2016 AACR.